3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
5
Lymphoma
3
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Stomatitis
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Postoperative
1
Pain
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Mucositis
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Prolymphocytic
1
Interventions
fludarabine phosphate
19
fludarabine
18
Cyclophosphamide
16
Tacrolimus
12
Whole-Body Irradiation
11
Melphalan
11
Mycophenolic Acid
10
Bortezomib
9
Busulfan
8
trametinib
7
Dexamethasone
7
thymoglobulin
6
Stem Cell Transplantation
6
Lenalidomide
6
Cyclosporine
6
Sirolimus
5
Nivolumab
5
Methotrexate
5
dabrafenib
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Granulocyte Colony-Stimulating Factor
4
Antilymphocyte Serum
4
Alemtuzumab
4
daratumumab
3
aldesleukin
3
Thiotepa
3
Specimen Handling
3
Ipilimumab
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Saline Solution
×
Plasma cell
×
Clear all
NCT05493800
2024-05-29
Capella
MitoImmune Therapeutics
Phase 2
Unknown
60 enrolled